The latest research findings with participation of the KKNMS

In this section we present our latest scientific publications. In our archive you will find a list of further publications since 2009.

First publications:

Publications 2016

Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study
By Schumacher et al, published by “MAGMA” (Vol. 29, no. 3, June 2016)

Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis
By Liu et al, published by “Am J Neuroradiol.” (Vol. 37, no. 4, April 2016)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
By Finke et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, no. 3, April 2016)

Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study
By Ayzenberg et al, published by “J Neurol.” (Vol. 263, no. 3, March 2016)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
By Schwab et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 3, February 2016)

Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
By Metz et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 3, no. 2, February 2016)

Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica
By Hertwig et al, published by “Multiple Sclerosis Journal” (Vol. 22, no. 2, February 2016)

Structural correlates for fatigue in early relapsing remitting multiple sclerosis
By Wilting et al, published by “European Radiology” (Vol. 26, no. 2, February 2016)

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses
By Kleiter et al, published by “Ann Neurol.” (Vol. 79, no. 2, February 2016)

Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration
By Deppe et al, published by “Multiple Sclerosis Journal” (Vol. 22, no. 1, January 2016)

Changing requirements and resulting needs for IT-infrastructure for longitudinal research in the neurosciences
By Buckow et al, published by “Neurosci Res.” (Vol. 102, January 2016)

In vivo visualization of (auto)immune processes in the central nervous system of rodents
By Schläger et al, published by “Methods Mol Biol.” (Vol. 1304, 2016)

Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases
By Spadaro M and Meinl E, published by “Methods “Mol Biol.” (Vol. 1304, 2016)

Publications 2015

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS
By Schrewe et al, published by “Journal of Neuroinflammation” (Vol. 12, no. 1, December 2015)

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis
By Luessi et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 14, December 2015)

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array
By Dankowski et al, published by “Genet Epidemiol.” (Vol. 39, no. 8, December 2015)

Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis
By Haas et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 12, October 2015)

Putaminal alteration in multiple sclerosis patients with spinal cord lesions
By Zimmermann et al, published by “Journal of Neural Transmission” (Vol. 122, no. 10, October 2015)

Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis
By Keller et al, published by “J Neuroinflammation” (Vol. 12, October 2015)

Class II HLA interactions modulate genetic risk for multiple sclerosis
By Moutsianas et al, published by “Nat Genet.” (Vol. 47, no. 10, October 2015)

Central Role of Th2 and Tc2 Lymphocytes in Multiple Sclerosis Pattern II Demyelinating Lesions
By Planas et al, published by “Annals of Clinical and Translational Neurology” (Vol. 2, no. 9, September 2015)

Relevance of Magnet Resonance Tomography in the Diagnosis and Assessment of Course of Disease in Patients with Multiple Sclerosis
By Lukas C and Sailer M, published by “Fortschr Neurol Psychiatr.” (Vol. 83, no. 9, September 2015)

Magnetresonanztomografie bei Patienten mit Multipler Sklerose: Relevanz in der Diagnose und Verlaufsbeurteilung
By Lukas C and Sailer M, published by “Klin Neurophysiol” (Vol. 46, no. 3, September 2015)

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
By Warnke et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 8, July 2015)

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
By Kuhle et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 8, July 2015)

Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9
By Lindner et al, published by “Brain” (Vol. 138, Pt 7, July 2015)

Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis
By Kolber et al, published by “Journal of Neurology” (Vol. 262, no. 6, June 2015)

γ-secretase directly sheds the survival receptor BCMA from plasma cells
By Laurent et al, published by “Nature Communications” (Vol. 6, June 2015)

Atrophy and structural variability of the upper cervical cord in early multiple sclerosis
By Biberacher et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 7, June 2015)

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases
By Rau et al, published by “Int J Mol Sci.” (Vol. 16, no. 7, June 2015)

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
By Bennett et al, published by “Multiple Sclerosis Journal” (Vol. 21, no. 6, May 2015)

B lymphocytes in neuromyelitis optica
By Bennett et al, published by “Neurol Neuroimmunol Neuroinflamm.” (Vol. 2, no. 3, May 2015)

A human post-mortem brain model for the standardization of multi-centre MRI studies
By Droby et al, published by “Neuroimage” (Vol. 110, April 2015)

Role of the innate and adaptive immune responses in the course of multiple sclerosis
By Hemmer et al, published by “Lancet Neurology” (Vol. 14, no. 4, April 2015)

Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis
By Metz et al, published by “Neurol Neuroimmunol Neuroinflamm” (Vol. 2, no. 3, April 2015)

Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies–conflicting results?
By Hemmer B., published by “Multiple Sclerosis Journal” (Vol. 21, no. 5, April 2015)

The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients
By Droby et al, published by “NeuroImage: Clinical” (Vol. 8, April 2015)

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc
By Stork et al, published by “Acta Neuropathol.” (Vol. 129, no. 3, March 2015)

Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial
By Rahn et al, published by “Trials” (Vol. 16, no. 1, March 2015)

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
By Spadaro et al, published by “Ann Clin Transl Neurol.” (Vol. 2, no. 3, March 2015)

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
By Villar et al, published by “Ann Neurol.” (Vol. 77, no. 3, March 2015)

Cross-recognition of a myelin peptide by CD8+ T cells in the CNS is not sufficient to promote neuronal damage
By Reuter et al, published by “Journal of Neuroscience” (Vol. 35, no. 12, March 2015)

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria
By Schippling et al, published by “Mult Scler.” (Vol. 21, no. 2, February 2015)
MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4
By Walsh et al, published by “J Clin Invest.” (Vol. 125, no. 2, February 2015)

Fingolimod treatment promotes regulatory phenotype and function of B cells
By Grützke et al, published by “Ann Clin Transl Neurol.” (Vol. 2, no. 2, February 2015)

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b
By Ingwersen et al, published by “Ann Clin Transl Neurol.” (Vol. 2, no. 1, January 2015)

Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands
By Halbgebauer et al, published by “Electrophoresis” (Vol. 36, no. 2, January 2015)

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis
By Grey et al, published by “J Neuroimmunol.” (Vol. 278, January 2015)

The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity
By Hoffmann et al, published by “J Immunol.” (Vol. 194, no. 2, January 2015)

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis
By Schwab et al, published by “Int Immunol.” (Vol. 27, no. 1, January 2015)

The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations
By Kowarik et al, published by “J Neuroinflammation” (Vol. 12, no. 19, January 2015)

Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with MS
By Fleischmann et al, published by “JAMA Neurol.” (Vol. 72, no. 1, January 2015)

Publications 2014

Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking
By Posevitz-Fejfár et al, published by “PLoS One” (Vol. 9, no. 12, December 2014)

A recoverable state of axon injury persists for hours after spinal cord contusion in vivo
By Williams et al, published by “Nat Commun.” (Vol. 5, Nr. 5683, December 2014)

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy
By Warnke et al, published by “Ann Neurol.” (Vol. 76, no. 6, December 2014)

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia
By Warnke et al, published by “Neurology” (Vol. 83, no. 23, December 2014)

Pervasive axonal transport deficits in multiple sclerosis models
By Sorbara et al, published by “Neuron” (Vol. 84, no. 6, December 2014)

Identical lesion morphology in primary progressive and relapsing-remitting MS–an ultrahigh field MRI study
By Kuchling et al, published by “Mult Scler.” (Vol. 20, no. 14, December 2014)

Review: Mode of action and clinical studies with fumarates in multiple sclerosis
By Salmen A and Gold R, published by “Exp Neurol.” (Vol. 262, Part A, December 2014)

Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS
By Koutrolos et al, published by “Acta Neuropathol Commun.” (Vol. 2, December 2014)

Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination
By Mohan et al, published by “Acta Neuropathol Commun.” (Vol. 2, December 2014)

Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer’s disease and frontotemporal lobar degeneration
By Oeckl et al, published by “J Proteome Res.” (Vol. 13, no. 11, November 2014)

Magnetic Resonance Imaging in Multiple Sclerosis – Patients’ Experiences, Information Interests and Responses to an Education Programme
By Brand et al, published by “PLoS One” (Vol. 9, no. 11:e113252, November 2014)

Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients
By Fleischer et al, published by “J Clin Neurol.” (Vol. 10, no. 4, October 2014)

Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation
By Beltrán et al, published by “Brain” (Vol. 137, Pt 10, October 2014)

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders
By Gnanapavan et al, published by “Neurology” (Vol. 83, no. 13, September 2014)

Review: Microglia: unique and common features with other tissue macrophages
By Prinz et al, published by “Acta Neuropathol.” (Vol. 128, no. 3, September 2014)

A unified cell biological perspective on axon-myelin injury
By Simons et al, published by “J Cell Biol.” (Vol. 206, no. 3, August 2014)

The investigation of acute optic neuritis: a review and proposed protocol
By Petzold et al, published by “Nat Rev Neurol.” (Vol. 10, no. 8, August 2014)

Human CD4+HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo
By Pankratz et al, published by “FASEB J.” (Vol. 28, no. 8, August 2014)

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells
By Schneider-Hohendorf et al, published by “J Exp Med.” (Vol. 211, Nr. 9, August 2014)

Review: Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis: In Search of Biomarkers
By Alvermann et al, published by “JAMA Neurol.” (Vol. 71, no. 7, July 2014)

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate
By Jarius et al, published by “J Neuroinflammation” (Vol. 11, no. 129, July 2014)

Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients
By Nischwitz et al, published by “Acta Neurol Scand” (Vol. 130, no. 1, July 2014)

Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions
By Schirmer et al, published by “Ann Neurol.” (Vol. 75, no. 6, June 2014)

Nurse-led immunotherapy DEcision Coaching In Multiple Sclerosis (DECIMS) – design and feasibility study for a cluster-randomised controlled trial
By Rahn et al, published by “MSJ” (Vol. 20, no. 7, June 2014)

Management of disease modifying treatments in neurological autoimmune diseases of the central nervous system
By Salmen et al, published by “Clin Exp Immunol” (Vol. 176, no. 2, May 2014)
Multiparametric optical analysis of mitochondrial redox signals during neuronal physiology and pathology in vivo
By Breckwoldt et al, published by “Nat Med.” (Vol. 20, no. 5, May 2014)

Neuromyelitis optica: clinical features, immunopathogenesis and treatment
By Jarius et al, published by “Clin Exp Immunol.” (Vol. 176, no. 2, May 2014)

Pathologic heterogeneity persists in early active multiple sclerosis lesions
By Metz et al, published by “Ann Neurol” (Vol. 75, no. 5, May 2014)

Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses
By Schweingruber et al, published by “Acta Neuropathol” (Vol. 127, no. 5, May 2014)

Review: Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
By Prinz M and Priller J, published by “J Nat Rev Neurosci.” (Vol. 15, no. 5, May 2014)

NF-κB signaling regulates myelination in the CNS
By Blank T and Prinz M, published by “Front Mol Neurosci.” (Vol. 7, no. 47, May 2014)

B cells in multiple sclerosis: good or bad guys?: An article for 28 May 2014 – World MS Day 2014
By Hoffmann F and Meinl E, published by “Eur J Immunol.” (Vol. 44, no. 5, May 2014)

Review: B cells in MS and NMO: pathogenesis and therapy
By Krumbholz M and Meinl E, published by “Semin Immunopathol.” (Vol. 36, no. 3, May 2014)

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity
By Breuer et al, published by “Ann Neurol.” (Vol. 75, no. 5, May 2014)

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants
By Sundqvist et al, published by “PLoS Pathog.” (Vol. 10, no. 4, April 2014)

Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis
By Hoepner et al, published by “J Cent Nerv Syst Dis.” (Vol. 6, April 2014)

Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis
By Senel et al, published by “PLoS One” (Vol. 9, no. 4: e88680, April 2014)

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
By Shen et al, published by “Nature” (Vol. 507, no. 7492, March 2014)

Comment: New evidence for teriflunomide in multiple sclerosis
By Kieseier BC and Wiendl H, published by “Lancet Neurol.” (Vol. 13, no. 3, March 2014)

Review: To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis
By Schirmer et al, published by “Mult Scler.” (Vol. 20, no. 3, March 2014)

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis
By Deppe et al, published by “Neuroimage Clin.” (Vol. 6, no. 4, March 2014)

The neuroinflammation biobank in the Department of Neurology, University Hospital Muenster, Germany
By Posevitz-Fejfár A and Wiendl H, published by “Biopreserv Biobank” (Vol. 12, no. 1, February 2014)

Selective accumulation of pro-inflammatory T cells in the intestine contributes to the resistance to autoimmune demyelinating disease
By Berer et al, published by “PLoS One” (Vol. 9, no. 2:e87876, February 2014)

The fraction of varicella zoster virus-specific antibodies among all intrathecally-produced antibodies discriminates between patients with varicella zoster virus reactivation and multiple sclerosis
By Otto et al, published by “Fluids Barriers CNS” (Vol. 11, no. 1:3, February 2014)

Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease
By Kraus et al, published by “Neurology” (Vol. 82, no. 6, February 2014)

Review: Biomarkers of treatment response in multiple sclerosis
By Buck D and Hemmer B, published by “Expert Rev Neurother.” (Vol. 14, no. 2, February 2014)

Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases
By Kowarik et al, published by “J Neurol.” (Vol. 261, no. 1, January 2014)

Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain
By Paul F and Wattjes MP, published by “Lancet” (Vol. 383, no. 9912, January 2014)

Onset of secondary progressive phase and long-term evolution of multiple sclerosis
By Scalfari et al, published by “J Neurol Neurosurg Psychiatry” (Vol. 85, no. 1, January 2014)

Publications 2013

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
By International Multiple Sclerosis Genetics Consortium, published by “Nat Genet.” (Vol. 45, no. 11, November 2013)

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
By Teunissen et al, published by “Mult Scler.” (Vol. 19, no. 13, November 2013)

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis
By Warnke et al, published by “Neurology” (Vol. 81, no. 16, October 2013)

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients
By Selter et al, published by “Multiple Sclerosis Journal” (Vol. 19, no. 11, October 2013)

Hunting for autoantibodies in multiple sclerosis
By Hemmer B and Srivastava R, published by “Neurology” (Vol. 81, no. 11, September 2013)

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
By Schwab et al, published by “Neurology” (Vol. 81, no. 10, September 2013)

An assay to quantify species-specific anti-JC virus antibody levels in MS patients
By Warnke et al, published by “Mult Scler J” (Vol. 19, no. 9, August 2013)

T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients
By Balint et al, published by “Neurology” (Vol. 81, no. 9, August 2013)

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis
By Galea et al, published by “European Journal of Neurology” (Vol. 20, no. 7, July 2013)

A combination of fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real time during CNS autoimmunity
By Lodygin et al, published by “Nature Medicine” (Vol. 19, no. 6, June 2013)

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls
By International Multiple Sclerosis Genetics Consortium, published by “Am J Hum Genet” (Vol. 92, no. 6, June 2013)

Neurons as targets for T cells in the nervous system
By Liblau et al, published by “Trends in Neurosciences” (Vol. 36, no. 6, June 2013)

MANBA, CXR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis
By International Multiple Sclerosis Genetics Consortium, published by “Brain” (Vol. 136, no. 6, June 2013)

Fine-tuning of Regulatory T-Cell Function: the Role of Calcium Signals and Naïve Treg for Treg Deficiency in Multiple Sclerosis?
By Schwarz et al, published by “J Immunol” (Vol. 190, no. 10, May 2013)

Mitoxantrone-related acute leukemia in MS: an open or closed book?
By Chan A und Lo-Coco F, published by “Neurology” (Vol. 80, Nr. 16, April 2013)

Cellular, subcellular and functional in vivo labeling of the spinal cord using vital dyes
By Romanelli et al, published by “Nat Protoc.” (Vol 8, no. 3, March 2013)

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk
By Lill et al, published by “J Med Genet.” (Vol. 50, no. 3, March 2013)

Genetic Variants in the Immunoglobulin Heavy Chain Locus are Associated with the Gamma Globulin Index in Multiple Sclerosis
By Buck et al, published by “Annals of Neurology” (Vol. 73, no. 1, January 2013)

Publications 2012

Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis
By Décard et al, published by “J Neurol Neurosurg Psychiatry” (Vol. 83, no. 12, December 2012)

Neurofascin as a target for autoantibodies in peripheral neuropathies
By Ng et al, published by “Neurology” (Vol. 79, no. 23, December 2012)

B cells and antibodies in multiple sclerosis pathogenesis and therapy
By Krumbholz et al, published by “Nat Rev Neurol” (Vol. 8, no. 11, November 2012)

Therapeutic monitoring of immunotherapies in autoimmune diseases
By von Ahsen N und Chan A, published by “Current pharmaceutical design” (Vol. 18, no. 29, October 2012)

Prospects of transcript profiling for mRNAs and MicroRNAs using formalin-fixed and paraffin-embedded dissected autoptic multiple sclerosis lesions
By Eisele et al, published by “Brain Pathol.” (Vol. 22, no. 5, September 2012)

Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects
By Lill et al, published by “J Med Genet.” (Vol. 49, no. 9, September 2012)

T cells become licensed in the lung to enter the central nervous system
By Odoardi et al, published by “Nature” (Vol. 488, no. 7413, August 2012)

Biocompatibility of a genetically encoded calcium indicator in a transgenic mouse model
By Direnberger et al, published by “Nature Communications ” (Vol. 3, no. 1031, August 2012)

Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor(+) Regulatory T Cells
By Yogev et al, published by “Immunity” (Vol. 37, no. 2, August 2012)

The ambivalent role of apoptosis in experimental autoimmune
By Reichardt HM and Lühder F, published by “Curr Pharm Des” (Vol. 18, no. 29, July 2012)

The Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis
By Srivastava et al, published by “N Eng J Med” (Vol. 367, no. 2, July 2012)

Anti-JCV antibody prevalence in a German MS cohort
By Warnke et al, published by “Multiple Sclerosis Journal” (Vol. 18, no. 7, July 2012)

Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis
By Elliott et al, published by “BRAIN” (Vol. 135, no. 6, June 2012)

Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
By Derfuss T and Meinl E, published by “Curr Opin Neurol.” (Vol. 25, no. 3, June 2012)

Single nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-ß therapy in multiple sclerosis patients
By Weber et al, published by ” The Pharmacogenomics Journal” (Vol. 12, no. 3, June 2012)

Commensal gut flora and brain autoimmunity: a love or hate affair?
By Berer et al, published by “Acta Neuropathologica” (Vol. 123, No. 5, May 2012)

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
By Kowarik et al, published by “J Neuroinflammation” (Vol. 9, no. 93, May 2012)

Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more
By Mayer et al, published by “Therapeutic Advances in Neurological Disorders” (Vol. 5, no. 3, May 2012)

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
By Trampe et al, published by “Neurology” (Vol. 78, no. 22, May 2012)

Immunological and clinical consequences of treating a patient with natalizumab
By Schwab et al, published by “Multiple Sclerosis Journal” (Vol. 18, no. 3, March 2012)

Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration
By Colombo et al, published by “The Journal of Experimental Medicine” (Vol. 209, no. 3, March 2012)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
By Metz et al, published by “Acta Neuropathologica” (Vol. 123, no. 2, February 2012)

Primary oligodendrocyte death does not elicit anti-CNS immunity
By Locatelli et al, Epub ahead of print “Nature Neuroscience” (26th February 2012)

An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis
By Schmidt et al, published by “Neuroimage” (Vol. 59, no. 4, February 2012)

Fatal PML associated with efalizumab therapy. Insights into integrin αLβ2 in JC virus control
By Schwab et al, published by “Neurology” (Vol. 78, no. 7, February 2012)

Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample
By Lill et al, published by “Neurogenetics” (Vol. 13, no. 1, February 2012)

Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination
By Lee et al, published by “Acta Neuropathologica” (Vol. 123, no. 2, February 2012)

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
By Stroet et al, published by “Therapeutic Advances in Neurological Disorders” (Vol. 5, no. 2, January 2012)

Publications 2011

B cells undergo unique compartmentalized redistribution in multiple sclerosis
By Haas et al, published by “Journal of Autoimmunity” (Vol. 37, no. 4, December 2011)

Ion channels in autoimmune neurodegeneration
By Ehling et al, published by “FEBS letters” (Vol. 585, no. 23, December 2011)

Autoimmune disease in the brain – how to spot the culprits and how to keep them in check
By Flügel et al, published by “Journal of the Neurological Sciences” (Vol. 311, s 1 , December 2011)

Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS
By Dann et al, published by “Nature Neuroscience  ” (Vol. 15, no. 1, December 2011)

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors
By Saure et al, published by “Archives of Neurology” (Vol. 68, no. 11, November 2011)

Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
By Berer et al, published by “Nature” (Vol. 479, no. 7374, November 2011)

Pharmacogenomics in Neurology: Current State and Future Steps
By Chan et al, published by “Annals of Neurology” (Vol. 70, no. 5, November 2011)

Diagnostik der Multiplen Sklerose – 2010 Revision der Mc-Donald-Kriterien
By Klotz et al, published by “Der Nervenarzt” (Vol. 82, no. 10, October 2011)

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
By Lehmann-Horn et al, published by “Journal of Neuroinflammation” (Vol. 8, no. 146, October 2011)

Treatment of multiple sclerosis: current concepts and future perspectives
By Buck D. and Hemmer B., published by “Journal of Neurology” (Vol. 258, no. 10, October 2011)

Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab
By Warnke et al, published by “Der Nervenarzt” (Vol. 82, no. 10, October 2011)

Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis
By Schweingruber et al, published by “Journal of  Immunology” (Vol. 187, no. 8, October 2011)

ATP-Binding Cassette Transporters in Inflammatory Brain Disease
By Chan et al, published by “Current Pharmaceutical Design” (Vol. 17, no. 26, September 2011)

Age and disability accumulation in multiple sclerosis
By Scalfari et al, published by “Neurology” (Vol. 77, no. 13, September 2011)

CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats
By Miljković et al, published by “Immunobiology” (Vol. 216, no. 9, September 2011)

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
By: The International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2), published by “Nature” (Vol. 476, no. 7359, August 2011)

Association between Walking Speed and Age in Healthy, Free-Living Individuals Using Mobile Accelerometry-A Cross-Sectional Study
By Schimpl et al, published by “PLoS One” (Vol. 6, no. 8, August 2011)

Evaluation of soluble HLA-G as a biomarker for multiple sclerosis
By Waschbisch et al, published by “Neurology” (Vol. 77, no. 6, August 2011)

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
By Pröbstel et al, published by “Neurology” (Vol. 77, no. 6, August 2011)

Development and validation of a new method to measure gait d speed using mobile accelerometry
By Schimpl et al, published by “PLoS One” (Vol. 6, no. 8, August 2011)

Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels
By Bobak et al, published by “Biochimica et Biophysica Acta (BBA) – Biomembranes” (Vol. 1808, no. 8, August 2011)

Humoral autoimmunity in multiple sclerosis
By Meinl et al, published by “Journal of the Neurological Sciences” (Vol. 306, no. 1-2, July 2011)

More CLEC16A gene variants associated with multiple sclerosis
By Nischwitz et al, published by “Acta Neurologica Scandinavica” (Vol. 123, no. 6, June 2011)

Risks and benefits of multiple sclerosis therapies: need for continual assessment?
By Kieseier et al, published by “Current Opinion in Neurology” (Vol. 24, no.3, June 2011)

PML under natalizumab: Initial possibilities for risk stratification?
By Warnke et al, published by “Der Nervenarzt” (Vol. 82, no. 4, April 2011)

Long-term follow-up of patients with Neuromyelitis optica after repeated therapy with rituximab
By Pellkofer et al, published by “Neurology” (Vol. 76, no. 15, April 2011)

Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin
By Obermeier et al, published by “Journal of Neuroimmunology” (Vol. 233, no. 1-2, April 2011)

A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
By Nikic et al, published by “Nature Medicine” (Vol. 17, no. 4, April 2011)

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders
By Haghikia et al, published by “PLoS One” (Vol. 6, no. 4, April 2011)

EPIBLASTER-Fast exhaustive two-locus epistasis detection strategy using graphical processing units
By Kam-Thong et al, published by “European Journal of Human Genetics” (Vol. 19, no. 4, April 2011)

Influence of the HLA-DRB1 Genotype on antibody development to Interferon Beta in Multiple Sclerosis
By Buck et al, published by “Archives of Neurology” (Vol. 68, no. 4, April 2011)

I B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF- B in the CNS
By Raasch et al, published by “BRAIN” (Vol. 134, no. 4, April 2011)

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of MS patients
By Kowarik et al, published by “Neurology” (Vol. 76, no. 14, April 2011)

Intracerebral Human Regulatory T Cells: analysis of CD4+CD25+FOXP3+ T Cells in Brain Lesions and Cerebrospinal Fluid of Multiple Sclerosis Patients
By Fritzsching et al, published by “PLoS One” (Vol. 6, no. 3, March 2011)

The interleukin-7 receptor a chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis
By Haas et al, published by “European Journal of Immunology” (Vol. 41, no. 3, March 2011)

Is it possible to measure mobility deficits of patients suffering from multiple sclerosis?
By Schlesinger et al, published by “Klinische Neurophysiologie” (Vol. 42, no. 1, March 2011)

Therapy for Multiple Sclerosis with Monoclonal Antibodies: Updated Recommendations for the Use of Natalizumab in the Framework of an Expert’s Meeting
By Hartung et al, published by “Aktuelle Neurologie” (Vol. 38, no. 1, February 2011)

Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients
By Bittner et al, published by “Arthritis Research & Therapy” (Vol. 13, no. 1, February 2011)

Janus head: the dual role of HLA-G in CNS immunity
By Huang et al, published by “Cellular and Molecular Life Sciences”
(Vol. 68, no. 3, February 2011)

Microglia in the CNS: Immigrants from another world
By M. Prinz and A. Mildner, published by “GLIA” (Vol. 59, no. 2, February 2011)

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus
By Warnke et al, published by “Multiple Sclerosis” (Vol. 17, no. 2, February 2011)

The emerging role of miRNAs in multiple sclerosis
By Junker et al, published by “Nature Reviews Neurology” (Vol. 7, no. 1, January 2011)

Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica
By Kalluri et al, published by “PLoS One” (Vol. 6, no. 1, January 2011)

Publications 2010

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in multiple sclerosis patients
By Schneider-Hohendorf et al, published by “European Journal of Immunology” (Vol. 40, no. 12, December 2010)

A Data Protection Scheme for Medical Research Networks: Review after Five Years of Operation
By Helbing et al, published by “Methods Inf Med” (Vol. 49, no. 6, December 2010)

Glatiramer Acetate attenuates pro-inflammatory T Cell responses but does not directly protect neurons from inflammatory cell death
By Herrmann et al, published by “American Journal of Pathology” (Vol. 177, no. 6, December 2010)

Genetic proof for the transient nature of the Th17 phenotype
By Kurschus et al, published by “European Journal of Immunology” (Vol. 40, no. 12, December 2010)

Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis
By Doerck et al, published by “Plos one” (Vol. 5, no. 11, November 2010)

ESPED 2009 – Bericht des Beirats
By Berner et al, published by “Monatsschrift Kinderheilkunde” (Vol. 158, no. 11, November 2010)

B Cells participate in thymic negative selection of murine auto-reactive CD4+ T Cells
By F. Frommer and A. Waisman, published by “Plos one” (Vol. 5, no. 10, October 2010)

Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis
By Chan et al, published by “Multiple Sclerosis Journal” (Vol. 16, no. 10, October 2010)

Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis
By Nischwitz et al, published by “Journal of Neuroimmunology” (Vol. 227, no. 1-2, October 2010)

Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica
By Kalluri et al, published by “Archives of Neurology” (Vol. 67, no. 10, October 2010)

Extracellular matrix in multiple sclerosis lesions: fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells
By Mohan et al, published by “Brain pathology” (Vol. 20, no. 5, September 2010)

T cell vaccination induces the elimination of EAE effector T cells: analysis using GFP-transduced, encephalitogenic T cells
By Volovitz et al, published by “Journal of Autoimmunity” (Vol. 35, no. 2, September 2010)

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
By Linker et al, published by “Brain” (Vol. 133, no. 8, August 2010)

A Practical guide to pediatric multiple sclerosis
By P. Huppke and J. Gärtner, published by “Neuropediatrics” (Vol. 41, no. 4, August 2010)

Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis
By Heidbrink et al, published by “Brain, Behavior, and Immunity” (Vol. 24, no. 6, August 2010)

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies
By Waschbisch et al, published by “Journal of Neuroimmunology” (Vol. 225, no. 1-2, August 2010)

Upregulation of K2P5.1 Potassium Channels in Multiple Sclerosis
By Bittner et al, published by “Annals of Neurology” (Vol. 68, no. 1, July 2010)

Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system
By Cordiglieri et al, published by “Brain” (Vol. 133, no. 7, July 2010)

Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases
By Selter et al, published by “Neurology” (Vol. 74, no. 21, May 2010)

An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in Multiple Sclerosis
By Schwab et al, published by “Journal of Immunology” (Vol. 184, no. 9, May 2010)

Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis
By Kleiter et al, published by “Brain” (Vol. 133, no. 4, April 2010)

The antibody response to oligodendrocyte specific protein in multiple sclerosis
By Aslam et al, published by “Journal of Neuroimmunology” (Vol. 221, April 2010)

MS-Datenbank erleichtert Forschung
By Daumer et al, published by “Ärztliche Praxis Neurologie & Psychiatrie“ (no. 1, January 2010)

Knocking at the brain’s door: intravital two-photon imaging of autoreactive T cell interactions with CNS structures
By N. Kawakami and A. Flügel, published by “Seminars in Immunopathology” (Vol. 32, no. 3, September 2010)

Beneficial brain autoimmunity?
By H. Wekerle and R. Hohlfeld, published by “Brain” (Vol. 133, no. 8, August 2010)

Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury
By Derfuss et al, published by “Journal of Molecular Medicine” (Vol. 88, no. 8, August 2010)

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis
By Aktas et al, published by “Trends in Neuroscience” (Vol. 33, no. 3, March 2010)

Publications 2009

Antibodies to Native Myelin Oligodendrocyte Glycoprotein in Children with Inflammatory Demyelinating Central Nervous System Disease
By Brilot et al, published by “Annals of Neurology” (Vol. 66, no. 6, December 2009)

Glatiramer acetate improves regulatory T-cell function by expansion of naïve CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis
By Haas et al, published by “Journal of Neuroimmunology” (Vol. 216, December 2009)

Prognosis of the individual course of disease: the elements of time, hetereogeneity and precision
By Daumer et al, published by “Journal of Neurological Sciences” (Vol. 287, November 2009)

Intrathecal Pathogenic Anti-Aquaporin-4 Antibodies in Early Neuromyelitis Optica
By Bennett et al, published by “Annals of Neurology” (Vol. 66, no. 5, November 2009)

A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis
By Comabella et al, published by “Brain” (Vol. 132, no. 12, September 2009)

Specific central nervous system recruitment of HLA-G regulatory T Cells in multiple sclerosis
By Huang et al, published by “Annals of Neurology” (Vol. 66, no. 2, August 2009)

T cell suppression by naturally occurring HLA-G-expressing regulatory CD4 T cells is IL-10-dependent and reversible
By Huang et al, published by “Journal of Leukocyte Biology” (Vol. 86, August 2009)

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis
By Cotte et al, published by “Brain” (Vol. 132, no. 9, July 2009)

The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE
By Zozulya et al, published by “European Journal of Immunology” (Vol. 39, no. 6, June 2009)

Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants
By Kroner et al, published by “The American Journal of Pathology” (Vol. 174, no. 6, June 2009)

Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory Immune Responses in the CNS
By Zozulya et al, published by “The Journal of Neuroscience” (Vol. 29, no. 1, January 2009)